Road to Victories

Brian Sabol Patient

Brian was diagnosed with multiple myeloma in 2015, and since then has experienced a variety of treatments. He credits the work of the MMRF for making those treatments available, and now is enthusiastically joining up with the MMRF and Janssen Oncology for the Vermont to Quebec challenge. Brian heard about the R2V program through patient friend and fellow rider Tim Nash. These two are looking forward to cycling together and supporting one another both on the road and back home in their support group.

https://give.themmrf.org/BrianSabol2022Maine

Grateful…And Paying it Forward

Brian Sabol

If it weren’t for the research spearheaded by the Multiple Myeloma Research Foundation (MMRF), I might not have been here to write this blog and take part in this ride.

09/08/2019

How I got involved with The MMRF

Brian Sabol

Sitting and staring at a blank sheet of (virtual) paper thinking: “You’ve never blogged, never done anything on Social Media, and never have done anything like this before. What were…

05/13/2019

The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $400 million and directs nearly 90% of the total funds to research and related programs. Learn more and sign up to receive news and resources from the MMRF.

Learn More

Sponsored by

At Janssen Oncology, we’re shaping the future of cancer treatment. In the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.

About Janssen Oncology

Click below to learn more about a treatment option for multiple myeloma. If you’re also interested in getting more information from Janssen, sign up for ongoing communications.

Learn More